AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 11, 2024
The Drugs Technical Advisory Board (DTAB) of the Union health ministry has once again recommended prohibiting the manufacture, sale and distribution of pain relief drug combination S(+) etodolac+paracetamol, after considering a sub-committee report.
Pharmaceutical Technology
APRIL 11, 2024
The oral drug, which gained UK approval in September 2023, is used for the prevention of both chronic and episodic migraines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
APRIL 11, 2024
The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 11, 2024
Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
APRIL 11, 2024
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
Pharmaceutical Technology
APRIL 11, 2024
From nanoparticles to transdermal patches, Pharmaceutical Technology takes a look at the latest in drug delivery technologies for women's health.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
APRIL 11, 2024
Over the past two decades, there has been a marked increase in obesity rates among US adults, with projections indicating a continuing upward trend.
BioSpace
APRIL 11, 2024
The American Society of Health-System Pharmacists has released statistics showing the number of active and ongoing U.S. drug shortages has reached 323, the highest number since it began tracking the data.
Pharmaceutical Technology
APRIL 11, 2024
Pharmaceutical Technology has listed the leading suppliers of pharmaceutical filtration equipment and purification solutions. Download here.
pharmaphorum
APRIL 11, 2024
Discover effective strategies to overcome barriers to healthcare providers (HCP) and patients adopting digital health initiatives like apps. Learn how to increase engagement and improve outcomes.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
APRIL 11, 2024
The collaboration pact will see Rallybio gaining a $6.6m equity investment from J&J to further a natural history study of FNAIT.
Fierce Pharma
APRIL 11, 2024
The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea. | The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea.
Pharmaceutical Technology
APRIL 11, 2024
Alpine’s lead asset, povetacicept, is slated to enter Phase III trials in the second half of this year.
BioPharma Reporter
APRIL 11, 2024
Specific doses of Eli Lillyâs GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act â fast.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
APRIL 11, 2024
The $9m French funding is for Phase III registrational trial for OSE’s Tedopi as a second-line treatment for NSCLC.
BioSpace
APRIL 11, 2024
Vertex Pharmaceuticals on Wednesday announced it is acquiring clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash, the largest acquisition so far this year.
Pharmaceutical Technology
APRIL 11, 2024
With specialised production facilities for HPAPIs in great demand, what are the key challenges in manufacturing?
Fierce Pharma
APRIL 11, 2024
After investigations into the FDA’s response to severe drug shortages and other issues, the House Committee on Oversight and Accountability finally had its long-awaited chance to grill the agency’s | FDA Commissioner Robert Califf, M.D., told lawmakers that the agency, as the "referee," needs to be given more authority in order to preemptively halt drug shortages.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
APRIL 11, 2024
Data presented the American Association for Cancer Research’s annual meeting sparked hope that we could be getting closer to treating pancreatic cancer, glioblastoma and other particularly difficult tumors.
pharmaphorum
APRIL 11, 2024
Discover the latest insights and trends from BIO-Europe Spring conference, focusing on green shoots and cautious optimism in the industry. Learn about the latest funding opportunities and more.
XTalks
APRIL 11, 2024
Approaches to help better understand the complexities of brain function are key to advancing the development of novel treatments for Alzheimer’s disease. In recent years, researchers have increasingly recognized the value of biomarkers in Alzheimer’s disease in several areas, including offering biological insights into the disease’s pathophysiology, developing diagnostic tools for earlier disease detection, monitoring disease progression and evaluating the efficacy of new treatments.
BioSpace
APRIL 11, 2024
Moderna Thursday said it paused plans to build an mRNA manufacturing facility in Kenya to buy time to assess vaccine demand after being hit with $1 billion in losses and write-downs due to canceled orders.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Pharma Times
APRIL 11, 2024
RTIs account for around 60% of global antibiotic prescribing and are a key driver of AMR
BioSpace
APRIL 11, 2024
On the heels of withdrawing Relyvrio from the U.S. and Canadian markets, Amylyx is now charting a path in Wolfram syndrome with promising interim Phase II data for its lead asset AMX0035.
Fierce Pharma
APRIL 11, 2024
In a case so old that it predates Pfizer’s 2009 acquisition of Wyeth, the companies and a class-action group of direct drug purchasers have agreed to
BioSpace
APRIL 11, 2024
The U.S. Department of Justice has filed a complaint against Regeneron alleging that the pharma knowingly omitted credit card price concessions for Eylea to inflate Medicare reimbursement rates.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
APRIL 11, 2024
A paper presented at the 2nd International Conference on Systems Medicine, AI, and Drug Repurposing proposes a novel approach to overcoming the financial barriers associated with repurposing generic drugs through… Source
pharmaphorum
APRIL 11, 2024
The European Parliament has voted through reforms to legislation regulating the pharma sector, which the industry claims could compromise competitiveness and patient care.
Pharma Times
APRIL 11, 2024
Prostate cancer is responsible for around 12,000 deaths a year in the UK and is the second biggest cause of death for men
pharmaphorum
APRIL 11, 2024
Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
201 
Let's personalize your content